恩威医药 reported revenue of ¥0.37B for the period ended 2026-06-30, -16.6% year on year. Net income was ¥0.02B, a 4.3% net margin on a 51.2% gross margin. The largest revenue line is 妇科类 at 34% of the total. Free cash flow for the period was ¥0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.37B | -16.6% |
| Gross profit | ¥0.19B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | -58.2% |
| Gross margin | 51.2% | Net margin 4.3% |
| Revenue Q/Q | +13.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 妇科类 | ¥0.13B | 34.1% |
| 大健康产品 | ¥0.09B | 24.4% |
| 感冒类 | ¥0.06B | 15.7% |
| 补益类 | ¥0.04B | 10.7% |
| 其他 | ¥0.04B | 9.6% |
| 儿科类 | ¥0.02B | 5.0% |
| 其他(补充) | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.18B | 48.8% |
| R&D | ¥0.00B | 0.6% |
| SG&A | ¥0.17B | 46.3% |
| Tax & other | ¥-0.00B | -0.2% |
| Item | Amount |
|---|---|
| Total assets | ¥1.44B |
| Total liabilities | ¥0.42B |
| Shareholders' equity | ¥1.02B |
| Equity / assets | 71.1% |
| Operating cash flow | ¥0.07B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.06B |
| Cash conversion (OCF / net income) | 412% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
德尔玛 ・ 诺思格 ・ 天元宠物 ・ 趣睡科技 ・ 亚华电子 ・ 凯格精机 ・ 通行宝 ・ 涛涛车业 ・ 蓝箭电子 ・ 信德新材 ・ 普莱得 ・ 南王科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies